Novartis drops after updating mid-term outlook
FROM THE WIRE · SEEKINGALPHA.COM
Novartis guides for 5% forex-adjusted sales growth from 2026 to 2031, below its prior 5%-6% outlook for 2025-2030, and shares fall.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA lower growth outlook from a major pharma company weighs on the shares.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Novartis guides for 5% forex-adjusted sales growth from 2026 to 2031.
- 02The prior outlook was 5%-6% for 2025-2030.
- 03Shares fall after the update.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets